GSK Pharma Q3 Review: Motilal Oswal Lowers Target Price Despite Profit Beat — Here’s Why by NDTV Profits | February 10, 2026 9:44 am | Latest Posts, Market, Trending News Considering the limited upside from current levels, the brokerage reiterates its Neutral stance on GSK Pharma.
